Search Result

Results for "

Lipoprotein

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LDLR (46) LOX-1 (1) 5-HT Receptor (1) Acyltransferase (2) Adrenergic Receptor (8) Akt (3) Amino Acid Derivatives (2) AMPK (1) Amyloid-β (2) ANGPTL (2) Antibiotic (4) Apical Sodium-Dependent Bile Acid Transporter (1) Apolipoprotein (23) Apoptosis (23) Aryl Hydrocarbon Receptor (3) ASK1 (1) ATGL (1) Autophagy (23) Bacterial (17) Biochemical Assay Reagents (9) Calcium Channel (3) CaMK (1) Carboxylesterase (CES) (1) Caspase (3) CETP (10) COX (2) Cytochrome P450 (9) DNA/RNA Synthesis (5) Drug Derivative (4) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (30) Environmental Pollutants (2) Epigenetic Reader Domain (1) ERK (3) Estrogen Receptor/ERR (1) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (2) Ferroptosis (7) Fluorescent Dye (12) FOXO (1) Free Fatty Acid Receptor (1) Fungal (1) FXR (6) G protein-coupled Bile Acid Receptor 1 (1) GLP Receptor (1) Glutathione Peroxidase (5) Glycosidase (1) GPR109A (1) HCV (1) Hedgehog (1) HMG-CoA Reductase (HMGCR) (28) Hydroxycarboxylic Acid Receptor (HCAR) (1) Imidazoline Receptor (8) Interleukin Related (6) Isotope-Labeled Compounds (15) JNK (1) Keap1-Nrf2 (2) Lipase (4) Liposome (3) LPL Receptor (5) LXR (5) MAPKAPK2 (MK2) (1) MDM-2/p53 (1) MicroRNA (2) Microsomal Triglyceride Transfer Protein (MTP) (2) Mitochondrial Metabolism (2) Mitophagy (8) MMP (5) mRNA (2) mTOR (1) Necroptosis (1) NF-κB (4) NO Synthase (1) p38 MAPK (5) PAI-1 (2) PCSK9 (16) Peptide-Drug Conjugates (PDCs) (2) Phosphatase (1) Phospholipase (14) PI3K (1) PKA (2) Platelet-activating Factor Receptor (PAFR) (2) Potassium Channel (10) PPAR (7) Protease Activated Receptor (PAR) (1) Proton Pump (1) RAR/RXR (1) Reactive Oxygen Species (ROS) (12) Reference Standards (22) ROR (4) SARS-CoV (2) Small Interfering RNA (siRNA) (2) Smo (1) SOD (1) Sodium Channel (1) Stearoyl-CoA Desaturase (SCD) (1) TGF-beta/Smad (1) Thrombin (1) Thyroid Hormone Receptor (6) TNF Receptor (3) Toll-like Receptor (TLR) (2) TRP Channel (1) VEGFR (2) Virus Protease (1) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (46) Cardiovascular Disease (107) Endocrinology (8) Infection (15) Inflammation/Immunology (48) Metabolic Disease (140) Neurological Disease (39)
Oligonucleotides:	Fillers (1) Emulsifiers (1) Solubilizing Agents (1) mRNA (2) Cationic Lipids (1) siRNA drugs (2) Antisense Oligonucleotides (6) Cholesterol (1) siRNAs (2)

275

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: LDLR LOX-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D1048

DiR Maximum Cited Publications 96 Publications Verification Cy7 DiC18	Fluorescent Dye	Cancer
DiR is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .

HY-D0083

DiI 55+ Cited Publications DiIC18(3)	Fluorescent Dye	Others
DiI is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .

HY-17504

Rosuvastatin Calcium 20+ Cited Publications Rosuvastatin hemicalcium; ZD 4522 Calcium	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-D0969

DiO 20+ Cited Publications DiOC18(3); 3,3'-Dioctadecyloxacarbocyanine perchlorate	Fluorescent Dye	Others
DiO is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .

HY-D1028

DiD perchlorate 35+ Cited Publications	Fluorescent Dye	Others
DiD is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins (Ex/Em = 633/665 nm) .

HY-17504A

Rosuvastatin 20+ Cited Publications ZD 4522	HMG-CoA Reductase (HMGCR) Autophagy Potassium Channel Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-116767

BLT-1 10+ Cited Publications Block lipid transport-1	HCV	Metabolic Disease Inflammation/Immunology
BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor .

HY-112540B

Acetoacetic acid sodium	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .

HY-NP013

*Oxidized low density lipoprotein* (mouse)** 4 Publications Verification Mouse ox-LDL	LDLR ROR β-catenin	Cardiovascular Disease
Oxidized low density lipoprotein (mouse) (Mouse ox-LDL) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration. Oxidized low density lipoprotein (mouse) can be used to construct an in vitro model of AS .

HY-N0483

Phillygenin 4 Publications Verification Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin	Reactive Oxygen Species (ROS)	Others
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.

HY-17504B

Rosuvastatin Sodium 20+ Cited Publications ZD 4522 Sodium; X-Plended Sodium; Crestor Sodium	HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Bacterial	Cardiovascular Disease Metabolic Disease Cancer
Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-P99646

Golocdacimab 2 Publications Verification MEDI6570	LOX-1	Metabolic Disease Inflammation/Immunology
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the *lectin-like oxidized low-density lipoprotein* receptor LOX-1.** By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus .

HY-14668

Lomitapide mesylate 5+ Cited Publications AEGR-733 mesylate; BMS-201038 mesylate	Microsomal Triglyceride Transfer Protein (MTP) mTOR LDLR Autophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8 ⁺ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia .

HY-112540

Acetoacetic acid 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .

HY-164036

Lolamicin	Antibiotic Bacterial	Infection
Lolamicin is an orally effective inhibitor that specifically targets the Gram-negative bacteria lipoprotein transport system LolCDE complex. It selectively inhibits the transmembrane transport of outer membrane lipoproteins by competitively binding to lipoprotein binding sites. Lolamicin destroys the integrity of the bacterial outer membrane, leading to cell death, and has both bactericidal and antibacterial activity. It has significant effects on multidrug-resistant Enterobacteriaceae pathogens (such as Escherichia coli and Klebsiella pneumoniae). Lolamicin can be used to inhibit the study of acute pneumonia, sepsis and other infections caused by Gram-negative bacteria .

HY-18778

Obicetrapib TA-8995; DEZ-001; AMG-899	CETP Apolipoprotein LPL Receptor LDLR	Cardiovascular Disease
Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .

HY-109523

Cerivastatin sodium 2 Publications Verification	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-113110

Cysteinylglycine L-Cysteinylglycine; Cys-Gly; H-Cys-Gly-OH	Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Cardiovascular Disease Cancer
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .

HY-P6306

CS-6253 1 Publications Verification	Apolipoprotein Amyloid-β	Neurological Disease Metabolic Disease
CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .

HY-NP203

*High density lipoprotein* (human)** HDL (human)	Apolipoprotein NO Synthase LPL Receptor Akt PI3K p38 MAPK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
High density lipoprotein (human) (HDL (human)) is a human-derived high-density lipoprotein. High density lipoprotein can cross the blood-brain barrier, and partially acts on endothelial nitric oxide synthase (eNOS) by activating surface receptors such as SR-B1 and S1P3R, as well as intracellular signaling cascades involving Akt, PI3K and MAPK, thereby inducing the production of NO in endothelial cells. High density lipoprotein (human) can be used in research related to type 2 diabetes, Alzheimer's disease, cancer and atherosclerosis .

HY-N0627

Kaempferol-7-O-β-D-glucopyranoside	LDLR	Others
Kaempferol-7-O-β-D-glucopyranoside is a flavonoid glycoside. Kaempferol-7-O-β-D-glucopyranoside exists in the root bark of Cudrania tricuspidata. Kaempferol-7-O-β-D-glucopyranoside inhibits Cu ²⁺-induced lipid peroxidation of low-density lipoprotein. Kaempferol-7-O-β-D-glucopyranoside possesses antioxidant activity and scavenges DPPH free radicals .

HY-112540A

Acetoacetic acid lithium 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-P2752

Lipoprotein lipase, Pseudomonas sp LPL	Endogenous Metabolite	Metabolic Disease Cancer
Lipoprotein lipase, Pseudomonas sp (LPL) is a multifunctional enzyme from adipose tissue, heart and skeletal muscle, islets and macrophages. Lipoprotein lipase promotes normal lipoprotein metabolism, delivery and utilization of tissue-specific substrates. Lipoprotein lipase catalyzes the rate-limiting step of lipids in blood circulation .

HY-145001

20-HC-Me-Pyrrolidine	LDLR CETP	Metabolic Disease
20-HC-Me-Pyrrolidine (compound AI-3d) is a potent Aster protein inhibitor with IC₅₀s of 0.11 μM, 0.06 μM, and 0.71 μM for Aster-A, Aster-B, and Aster-C, respectively. 20-HC-Me-Pyrrolidine blocks the ability of Asters to bind and transfer cholesterol. 20-HC-Me-Pyrrolidine also inhibits the movement of low-density lipoprotein (LDL) cholesterol to the endoplasmic reticulum (ER) .

HY-126356

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Liposome	Cardiovascular Disease
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-P10502

L57	LDLR	Infection
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC₅₀ of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-N5015

Rosmanol 1 Publications Verification	COX	Inflammation/Immunology Cancer
Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-117549

Ibrolipim NO-1886	Lipase	Cardiovascular Disease
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .

HY-P99822

Recaticimab SHR-1209	PCSK9	Metabolic Disease
Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .

HY-153491A

Olezarsen sodium ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium	Apolipoprotein	Cardiovascular Disease
Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .

HY-109567

Gemcabene PD-72953	LDLR	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-14456A

MAC13243 2 Publications Verification	Bacterial	Infection
MAC13243, an antibacterial agent, is an inhibitor of bacterial lipoprotein targeting chaperone, LolA. MAC13243 is an antibacterial agent with Gram-negative selectivity .

HY-158424

LSN3353871	LDLR	Cardiovascular Disease
LSN3353871 is a potent inhibitor of lipoprotein(a) (Lp(a)) that can binds to Kringle IV (KIV) 8, KIV7-8 and KIV5-8, with K_d of 756 nM, 605 nM and 423 nM, respectively. LSN3353871 disrupts the formation of Lp(a) with the IC50 of 1.69 μM. LSN3353871 has oral bioactivity .

HY-P10697A

VH4127 TFA	LDLR	Metabolic Disease
VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a K_D of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .

HY-P10502A

L57 acetate	LDLR	Others
L57 acetate is a *Low-density lipoprotein* receptor-related protein 1 (LRP1)-binding peptide. L57 acetate exhibits high affinity to LRP1 with K_i** of 45 nM. L57 acetate exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 acetate can be utilized as the carrier for CNS drug delivery .

HY-177640

Lepodisiran LY3819469	Small Interfering RNA (siRNA)	Metabolic Disease
Lepodisiran is an siRNA targeted to lipoprotein(a).

HY-DY1013

DiR (solution)	Fluorescent Dye	Cancer
DiR (solution) is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins . Solvent and concentration: DMSO: 5 mM

HY-100469

LXRβ agonist-2	LXR	Inflammation/Immunology
LXRβ agonist-2 is an orally active and selective LXRβ agonist. LXRβ agonist-2 increases high-density lipoprotein cholesterol levels without elevating plasma triglyceride levels. LXRβ agonist-2 decreases lipid accumulation area in the aortic arch. LXRβ agonist-2 can be used for the research of atherosclerosis .

HY-19513

MB-07344	Thyroid Hormone Receptor	Metabolic Disease Endocrinology
MB-07344 is a potent thyroid hormone receptor (TR)-β agonist with a K_i of 2.17 nM. MB-07344 has additive cholesterol lowering activity in combination with Atorvastatin (HY-B0589) in rabbits, dogs and monkeys .

HY-46749

Muvalaplin tetrahydrochloride LY3473329 tetrahydrochloride	PAI-1	Cardiovascular Disease
Muvalaplin tetrahydrochloride (LY3473329) is an orally active reagent of lipoprotein (a) (Lp (a)). At present, research on Muvalaplin tetrahydrochloride oral reagent is ongoing .

HY-119741

Salacinol	Glycosidase Lipase	Metabolic Disease
Salacinol, compound found in Salacia reticulata, is an orally active α-glucosidase/lipase inhibitor. Salacinol inhibits enzymatic activity of intestinal maltase (IC₅₀ = 3.2 μg/mL, K_i = 0.31 μg/mL), sucrase (IC₅₀ = 0.84 μg/mL, K_i = 0.32 μg/mL), and isomaltase (IC₅₀ = 0.59 μg/mL, K_i = 0.47 μg/mL), and inhibits increases in serum glucose levels in sucrose-loaded rats. Salacinol also inhibits pancreatic lipase and lipoprotein lipase. Salacinol can be used for the research of diabetes mellitus .

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Endogenous Metabolite	Metabolic Disease
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-D1076

DiIC16(3)	Fluorescent Dye	Metabolic Disease
DiIC16(3) is a long-chain carbocyanine dye. Carbocyanine dyes are widely used as Di to label cells, organelles, liposomes, viruses and lipoproteins .

HY-153497A

Vupanorsen sodium IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium	ANGPTL	Metabolic Disease
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-P991574

MEDI-5884 REG-101	ATGL	Cardiovascular Disease
MEDI-5884 is a humanized IgG4Pκ neutralizing monoclonal antibody targeting Endothelial lipase (EL). MEDI-5884 inhibits EL and increases quantity (particularly phosphatidylinositols and cholesteryl esters) and function of high-density lipoproteins (HDL). MEDI-5884 can be used for cardiovascular disease like coronary artery disease (CAD) research .

HY-P6306A

CS-6253 TFA 1 Publications Verification	Apolipoprotein Amyloid-β	Neurological Disease Metabolic Disease
CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .

HY-W423578

LDLR regulator-1	LDLR	Cardiovascular Disease
LDLR regulator-1 (Compound 7b) is a regulator of the low-density lipoprotein receptor (LDLR), capable of increasing the mRNA expression of LDLR .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113046

5-Methyltetrahydrofolic acid Maximum Cited Publications 9 Publications Verification 5-Methyl THF; 5-MTHF	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-112540B

Acetoacetic acid sodium	Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .

HY-N0483

Phillygenin 4 Publications Verification Phillygenol; Epipinoresinol methyl ether; (+)-Phillygenin	Monophenols Oleaceae Classification of Application Fields Lignans Other Diseases Phenols Phenylpropanoids Forsythia suspensa (Thunb.) Vahl Plants Disease Research Fields Source Classification	Reactive Oxygen Species (ROS)
Phillygenin (Phillygenol) is an active ingredient from Forsythia with many medicinal properties, such as antioxidant, reducing blood lipid, inhibition of low density lipoprotein oxidation.

HY-112540

Acetoacetic acid 4 Publications Verification	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .

HY-N2118

Bilobetin 2 Publications Verification	Flavonoids Ginkgoaceae Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Biflavones Ginkgo biloba Disease Research Fields Source Classification	PPAR PKA Akt p38 MAPK ERK
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-113110

Cysteinylglycine L-Cysteinylglycine; Cys-Gly; H-Cys-Gly-OH	Natural Products Human Gut Microbiota Metabolites Microorganisms Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .

HY-W510159

5-O-Methylembelin	Lysimachia vulgarisL. Coumarins Phenylpropanoids Plants Primulaceae Source Classification	PCSK9
5-O-Methylembelin is a natural isocoumarin that inhibits PCSK9, *inducible degrader of the low-density lipoprotein* receptor (IDLR), and sterol regulatory element binding protein 2 (SREBP2)** mRNA expression .

HY-N7072

Grape seed extract 2 Publications Verification	Natural Products Classification of Application Fields Vitis vinifera cv. Zalema Metabolic Disease Plants Vitaceae Disease Research Fields Inflammation/Immunology Source Classification	Apoptosis
Grape seed extract is a natural product, with anti-inflammatory and anti-proliferative effects. Grape seed extract shows inhibitory activity on the fat-metabolizing enzymes pancreatic lipase and lipoprotein lipase. Grape seed extract induces apoptotic in human colorectal cancer cells .

HY-W013061

Propane-1,2,3-triyl tripalmitate	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Propane-1,2,3-triyl tripalmitate is a saturated fat. Propane-1,2,3-triyl tripalmitate enhances the lymphatic transport of Glycerol tristearate (HY-127035) .

HY-N0594

Deacetylasperulosidic Acid	Structural Classification Iridoids Classification of Application Fields Terpenoids Rubiaceae Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields Source Classification	SOD Interleukin Related TNF Receptor
Deacetylasperulosidic Acid is an orally active antioxidant. Deacetylasperulosidic Acid exerts a definite in vivo antioxidant effect and alleviates oxidative stress injury by enhancing SOD activity. In atopic dermatitis models, Deacetylasperulosidic Acid corrects Th2-skewed immune imbalance and reduces allergy-related factors; in immunosuppression models, it activates cellular immunity, enhances NK cell activity and IL-2 production. Deacetylasperulosidic Acid can be used in the research of atopic dermatitis .

HY-N0627

Kaempferol-7-O-β-D-glucopyranoside	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	LDLR
Kaempferol-7-O-β-D-glucopyranoside is a flavonoid glycoside. Kaempferol-7-O-β-D-glucopyranoside exists in the root bark of Cudrania tricuspidata. Kaempferol-7-O-β-D-glucopyranoside inhibits Cu ²⁺-induced lipid peroxidation of low-density lipoprotein. Kaempferol-7-O-β-D-glucopyranoside possesses antioxidant activity and scavenges DPPH free radicals .

HY-112540A

Acetoacetic acid lithium 4 Publications Verification	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-126573

Trilaurin	Structural Classification Classification of Application Fields Endogenous metabolite Disease Research Fields Lipid Source Classification Cancer	Endogenous Metabolite Biochemical Assay Reagents
Trilaurin is an orally active triglyceride. Trilaurin inhibits DMBA-induced, croton oil-promoted skin tumor formation in Swiss Webster mice. Trilaurin increases plasma high-density lipoprotein cholesterol and apolipoprotein A-I concentrations. Trilaurin is used as an occlusive skin conditioning agent and/or non-aqueous thickener in cosmetics .

HY-N0120

(E/Z)-Polydatin (E/Z)-Piceid	Structural Classification Stilbenes Classification of Application Fields Polygonaceae Reynoutria japonica Houtt. Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Drug Isomer
(E/Z)-Polydatin ((E/Z)-Piceid) is a mixture of the E/Z configurations of Polydatin (HY-N0120A). Polydatin can be isolated from Polygonum cuspidatum, grapes, peanuts, red wine, hop pellets, cocoa-containing products and chocolate products. Polydatin exhibits multiple biological properties, such as anti-platelet aggregation, anti-low-density lipoprotein oxidation, cardioprotective activity, anti-inflammatory and immunomodulatory functions. Polydatin shows favorable cytotoxic effects against various tumor cell lines, including cervical cancer cells, liver cancer cells, and nasopharyngeal carcinoma cells .

HY-126356

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Liposome
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-N5015

Rosmanol 1 Publications Verification	Classification of Application Fields Paramacrolobium coeruleum (Taub.) J.Léonard Labiatae Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	COX
Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-W007347

1,2-Cyclohexanedione	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Biochemical Assay Reagents LDLR
1,2-Cyclohexanedione is an arginine modification reagent. 1,2-Cyclohexanedione interferes with the degradation of low-density lipoprotein by modifying the arginine group in apolipoprotein. 1,2-Cyclohexanedione can be used in the research of familial hypercholesterolemia .

HY-N0686

Pseudoprotodioscin 1 Publications Verification	Structural Classification Classification of Application Fields Dioscorea nipponica Makino Metabolic Disease Plants Disease Research Fields Steroids Dioscoreaceae Source Classification	Fatty Acid Synthase (FASN) MicroRNA
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-126359

1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine SLPC; 18:0-18:2 PC	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	Endogenous Metabolite
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (SLPC; 18:0-18:2 PC) is an endogenous phospholipid marker molecule in the glycerophospholipid metabolic pathway. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine is a core component of the phospholipid bilayer of biological membranes and a key responsive lipid for radiation injury and cardiometabolic diseases. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine constitutes the phospholipid bilayers of cell membranes and high-density lipoprotein (HDL), and regulates the core activity of lipoprotein functional homeostasis. The content of 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine in mouse serum shows a significant dose-dependent decrease with increasing ionizing radiation dose, and its level in human HDL also decreases significantly in metabolic syndrome. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can serve as a biological dosimeter marker for ionizing radiation injury, and is used for rapid and accurate assessment of radiation absorbed dose in exposed individuals. 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine can also act as a lipidomics research target for cardiometabolic diseases such as lipid metabolic syndrome and early-onset coronary heart disease .

HY-113269

alpha-CEHC 1 Publications Verification	Microorganisms Source Classification	Drug Metabolite
alpha-CEHC is a water-soluble metabolite of alpha-tocopherol (α-TOH) with potential antioxidant activity. alpha-CEHC slightly inhibits macrophage-induced low-density lipoprotein (LDL) oxidation, and its inhibitory potency is concentration-dependent .

HY-N6738

Bafilomycin B1 1 Publications Verification	Infection Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Source Classification	Antibiotic Bacterial Fungal Proton Pump
Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets .

HY-119741

Salacinol	Structural Classification Natural Products Salacia reticulata Wight Celastraceae Plants Source Classification	Glycosidase Lipase
Salacinol, compound found in Salacia reticulata, is an orally active α-glucosidase/lipase inhibitor. Salacinol inhibits enzymatic activity of intestinal maltase (IC₅₀ = 3.2 μg/mL, K_i = 0.31 μg/mL), sucrase (IC₅₀ = 0.84 μg/mL, K_i = 0.32 μg/mL), and isomaltase (IC₅₀ = 0.59 μg/mL, K_i = 0.47 μg/mL), and inhibits increases in serum glucose levels in sucrose-loaded rats. Salacinol also inhibits pancreatic lipase and lipoprotein lipase. Salacinol can be used for the research of diabetes mellitus .

HY-N2339

Cholesteryl behenate 1 Publications Verification Cholesteryl docosanoate; Cholesterol behenate	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Steroids Source Classification	Endogenous Metabolite
Cholesteryl behenate is a cholesterol ester associated with the neutral core of low density lipoprotein Receptor-LDL complexes are taken up by lysosomes and hydrolyzed to release cholesterol from the esters.

HY-132187

Sphingosylphosphorylcholine	Structural Classification Natural Products Endogenous metabolite Source Classification	TGF-beta/Smad TRP Channel Apoptosis PAI-1
Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a K_d of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes .

HY-113110A

Cysteinylglycine TFA L-Cysteinylglycine TFA; Cys-Gly TFA; H-Cys-Gly-OH TFA	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) TFA is a dipeptide formed by the peptide bond connection of cysteine and glycine. Cysteinylglycine TFA is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine TFA can reduce trivalent iron to divalent iron, driving the redox cycle of iron, generating reactive oxygen species (ROS), stimulating oxidative reactions, inducing lipid peroxidation in human plasma LDL lipoproteins, and causing oxidative damage to DNA base. Cysteinylglycine TFA can be used as a biomarker to assess ischemic heart disease and breast cancer, etc ^[1][2][3][4].

HY-N15706

Luteolin-7-O-β-D-glucuronide methyl ester	Flavonoids Astragalus laxmannii Jacq. Flavones Labiatae Plants Source Classification	LDLR
Luteolin-7-O-β-D-glucuronide methyl ester is a flavonoid with antioxidative activity. Luteolin-7-O-β-D-glucuronide methyl ester exhibits potent antioxidative activity with an IC₅₀ of 3.05 μg/mL in the NBT superoxide scavenging assay. Luteolin-7-O-β-D-glucuronide methyl ester inhibits LDL oxidation induced by Cu ²⁺ with the IC₅₀ value is 71.13 μg/mL .

HY-W747992

Indicaxanthin	Structural Classification Natural Products Cactaceae Opuntia ficus-indica (L.) Mill. Plants Source Classification	Endogenous Metabolite
Indicaxanthin is a natural water-soluble betalain, presenting a yellow-orange color. Indicaxanthin possesses free radical scavenging ability and can inhibit lipid peroxidation, reducing the formation of malondialdehyde (MDA). Indicaxanthin can be used in the research of cardiovascular diseases and diabetes .

HY-113110R

Cysteinylglycine (Standard) L-Cysteinylglycine (Standard); Cys-Gly (Standard); H-Cys-Gly-OH (Standard)	Natural Products Human Gut Microbiota Metabolites Microorganisms Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS) DNA/RNA Synthesis
Cysteinylglycine (Standard) is the analytical standard of Cysteinylglycine. This product is intended for research and analytical applications. Cysteinylglycine is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions .

HY-112540AR

Acetoacetic acid lithium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Endogenous Metabolite Reference Standards
Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-N5015R

Rosmanol (Standard)	Paramacrolobium coeruleum (Taub.) J.Léonard Labiatae Phenols Polyphenols Plants Source Classification	Reference Standards COX
Rosmanol (Standard) is the analytical standard of Rosmanol. This product is intended for research and analytical applications. Rosmanol could inhibit the oxidation of low density lipoprotein (LPL) and significantly inhibit lipopolysaccharide induced iNOS and COX-2 expression, with anti-inflammatory effect.

HY-B1189R

Meglutol (Standard) Dicrotalic acid (Standard); 3-Hydroxy-3-methylglutaric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Reference Standards
Meglutol (Standard) is the analytical standard of Meglutol. This product is intended for research and analytical applications. Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-N0686R

Pseudoprotodioscin (Standard)	Structural Classification Natural Products Dioscorea nipponica Makino Plants Dioscoreaceae Source Classification	Reference Standards Fatty Acid Synthase (FASN) MicroRNA
Pseudoprotodioscin (Standard) is the analytical standard of Pseudoprotodioscin. This product is intended for research and analytical applications. Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides .

HY-N2118R

Bilobetin (Standard)	Structural Classification Flavonoids Ginkgoaceae Phenols Polyphenols Plants Biflavones Ginkgo biloba Source Classification	Reference Standards PPAR PKA Akt p38 MAPK ERK
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-N8353

Stachybotramide	Natural Products Microorganisms Source Classification	Others
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-density lipoprotein (HDL) to very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .

HY-N12385

Hispaglabridin B (R)-Hispaglabridin B	Structural Classification Natural Products Glycyrrhiza glabra Linn. Leguminosae Plants Source Classification	FOXO
Hispaglabridin B is an anti-oxidant agent that can be isolated from Glycyrrhiza glabra. Hispaglabridin B exhibits potent peroxynitrite scavenging activity with an IC₅₀ of 3.2 μM, and shows activity in a low-density lipoprotein (LDL) oxidation system . Hispaglabridin B is also a FoxO1 inhibitor . Hispaglabridin B improves muscle wasting by inhibiting catabolism in vivo and in vitro.

HY-182569

FR 111142	Structural Classification Natural Products Microorganisms Source Classification	VEGFR
FR 111142 is an angiogenesis inhibitor (IC₅₀ = 18.4 μM) and has anti-inflammatory activity (IC₅₀ = 20.6 μM). FR 111142 inhibits capillary-like tube formation as well as nitric oxide production in LPS (HY-D1056)-activated murine macrophages. FR 111142 enhances catabolism of low-density lipoprotein (LDL). FR 111142 does not induce significant cytotoxicity in human endothelial progenitor cells, nor affect cell viability of murine macrophages. FR 111142 can be used for the research of cancer, inflammatory diseases .

HY-N11737

Monasfluore A	Structural Classification Natural Products Microorganisms Source Classification	Drug Derivative
Monasfluore A is an azaphenanthrenone derivative with antioxidant activity. Monasfluore A inhibits LPS-induced nitric oxide production. Monasfluore A scavenges DPPH and superoxide anion free radicals. Monasfluore A exerts cellular antioxidant activity in oxidatively damaged colon adenocarcinoma cells. Monasfluore A shows no antiproliferative effect on human laryngeal cancer cells and colon adenocarcinoma cells .

Cat. No.	Product Name	Chemical Structure

HY-B0144AS1

Pitavastatin-d5 sodium
Pitavastatin-d₅ (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.

HY-113046S1

5-Methyltetrahydrofolic acid-13C6

5-Methyltetrahydrofolic acid- ¹³C₆ (5-Methyl THF- ¹³C₆) is ¹³C labeled 5-Methyltetrahydrofolic acid. 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

HY-17504AS1

Rosuvastatin-d6

Rosuvastatin-d₆ (ZD 4522-d₆) is deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-W015600S

2-Acetamidophenol-d3

2-Acetamidophenol-d₃ (Orthocetamol-d₃) is the deuterium labeled 2-Acetamidophenol (HY-W015600). 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC50s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe2+), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-B1189S

Meglutol-d3
Meglutol-d₃ is the deuterium labeled Meglutol . Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-17504BS1

Rosuvastatin-d6 sodium

Rosuvastatin-d₆ sodium is deuterium labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM. Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

HY-17504AS

Rosuvastatin-d3

Rosuvastatin-d₃ (ZD 4522-d₃) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM . Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals .

HY-17504BS2

Rosuvastatin-13C,d3 sodium

Rosuvastatin- ¹³C,d₃ sodium is ¹³C and deuterated labeled Rosuvastatin sodium (HY-17504B). Rosuvastatin Sodium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC₅₀ of 11 nM. Rosuvastatin Sodium potently blocks hERG current with an IC₅₀ of 195 nM . Rosuvastatin Sodium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Sodium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels .

HY-B0144S

Pitavastatin-d4 hemicalcium

Pitavastatin-d₄ (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].

HY-B0144AS3

Pitavastatin-d4-1 sodium

Pitavastatin-d₄-1 (NK-104-d₄-1) sodium is the deuterium labeled Pitavastatin sodium (HY-B0144B). Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC₅₀ of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .

HY-B0374S

Moxonidine-d4

Moxonidine-d₄ (BDF5895-d₄) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-109523S

Cerivastatin-d3 sodium

Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-W041171S

3-Chloro-L-tyrosine-13C6
3-Chloro-L-tyrosine- ¹³C₆ is the ¹³C labeled 3-Chloro-L-tyrosine . 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima .

HY-B0374S1

Moxonidine-d7

Moxonidine-d₇ is deuterated labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374AS

Moxonidine-13C,d3 hydrochloride

Moxonidine- ¹³C,d₃ hydrochloride is ¹³C and deuterated labeled Moxonidine hydrochloride (HY-B0374A). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374S2

Moxonidine-d3

Moxonidine-d₃ (BDF5895-d₃) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-126356S

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d11

1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine-d₁₁ is the deuterium labeled 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (HY-126356). 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine is a major phospholipid in low-density lipoprotein and belongs to the group of 1-acyl phosphatidylcholines. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine does not induce morphological changes in washed human platelets. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine can be used for the research of atherosclerosis and thrombotic diseases .

HY-D0932S

Sudan IV-d6

Sudan IV-d₆ (Solvent Red 24-d₆) is the deuterium labeled Sudan IV(HY-D0932). Sudan IV is an agonist of the aryl hydrocarbon receptor (AhR) that activates downstream signaling pathways and induces CYP1A1 expression. Sudan IV promotes CYP1A1 gene transcription by activating AhR-ARNT heterodimers and binding to exogenous response elements (XREs) on DNA, thereby enhancing drug metabolizing enzyme activity. Sudan IV can be used to study the toxicity mechanisms of industrial dyes and the effects of interactions with serum proteins (such as bovine serum albumin (BSA)) on their distribution in vivo. Sudan IV is a fat-soluble diazo dye that can be used to stain lipids, triglycerides, and lipoproteins on frozen sections .

HY-113046S2

5-Methyltetrahydrofolic acid-d4

5-Methyltetrahydrofolic acid-d₄ (5-Methyl THF-d₄) is the deuterium labeled 5-Methyltetrahydrofolic acid (HY-113046). 5-Methyltetrahydrofolic acid (5-Methyl THF) is the main circulating form of folic acid in the body and is involved in a variety of biochemical reactions. 5-Methyltetrahydrofolic acid regulates cardiovascular function by increasing the production of endothelin-1 (ET-1) in low-density lipoprotein-treated endothelial cells and can be used in the study of cardiovascular diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks